<figure><img src="image_1.png" /></figure>

HAL
open science

# Radioimmunotherapy of B-cell non-Hodgkin's lymphoma

Caroline Bodet-Milin, Ludovic Ferrer, Amandine Pallardy, Thomas Eugène,

Aurore Rauscher, Alain Faivre-Chauvet, Jacques Barbet, Françoise

Kraeber-Bodéré

► To cite this version:

Caroline Bodet-Milin, Ludovic Ferrer, Amandine Pallardy, Thomas Eugène, Aurore Rauscher, et al. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. Frontiers in Oncology, 2013, 3, pp.177. 10.3389/fonc.2013.00177. hal-04971658

HAL Id: hal-04971658

https://hal.science/hal-04971658v1

Submitted on 28 Feb 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_2.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_3.png" /></figure>

# Radioimmunotherapy of B-cell non-Hodgkin's lymphoma

Caroline Bodet-Milin<fnref n="1" />,<fnref n="2" />, Ludovic Ferrer<fnref n="2" />,<fnref n="3" />, Amandine Pallardy<fnref n="1" />, Thomas Eugène<fnref n="1" />, Aurore Rauscher<fnref n="1" />,<fnref n="2" />, Alain Faivre-Chauvet<fnref n="1" />,<fnref n="2" />, Jacques Barbet<fnref n="2" />,<fnref n="4" /> and Françoise Kraeber-Bodéré<fnref n="1" />,<fnref n="2" />,<fnref n="3" />*

**Edited by:**

Jean-Pierre Pouget, INSERM, France

**Reviewed by:**

Joshua Silverman, New York
University Medical Center, USA
Christopher Schultz, Medical College
of Wisconsin, USA
Michael Tomblyn, H. Lee Moffitt
Cancer Center and Research Institute,
USA

**\*Correspondence:**

Françoise Kraeber-Bodéré, Nuclear
Medicine Department, University
Hospital, 1 Place Alexis Ricordeau,
44093 Nantes, France
e-mail: francoise.bodere@chu-nantes.fr

This manuscript reviews current advances in the use of radioimmunotherapy (RIT) for the treatment of B-cell non-Hodgkin's lymphoma (NHL). RIT has been in use for more than 20 years and has progressed significantly with the discovery of new molecular targets, the development of new stable chelates, the humanization of monoclonal antibodies (MAbs), and the use of pretargeting techniques. Today, two products targeting the CD20 antigen are approved: ¹³¹I-tositumomab (Bexxar®), and ⁹⁰Y-ibritumomab tiuxetan (Zevalin®). ¹³¹I-tositumomab is available in the United States, and ⁹⁰Y-ibritumumab tiuxetan in Europe, the United States, Asia, and Africa. RIT can be integrated in clinical practice using non-ablative activities for treatment of patients with relapsed or refractory follicular lymphoma (FL) or as consolidation after induction chemotherapy in front-line treatment in FL patients. Despite the lack of phase III studies to clearly define the efficacy of RIT in the management of B lymphoma in the era of rituximab-based therapy, RIT efficacy in NHL has been demonstrated. In relapsing refractory FL and transformed NHL, RIT as a monotherapy induces around 30% complete response with a possibility of durable remissions. RIT consolidation after induction therapy significantly improves the quality of the response. Dose-limiting toxicity of RIT is hematological, depending on bone marrow involvement and prior treatment. Non-hematological toxicity is generally low. Different studies have been published assessing innovative protocols of RIT or new indications, in particular treatment in patients with aggressive lymphomas. High-dose treatment, RIT as consolidation after different therapeutic induction modalities, RIT in first-line treatment or fractionated RIT showed promising results. New MAbs, in particular humanized MAbs, or combinations of naked and radiolabeled MAbs, also appear promising. Personalized dosimetry protocols should be developed to determine injected activity.

**Keywords:** radioimmunotherapy, monoclonal antibody, CD20, CD22, dosimetry

## INTRODUCTION

B-cell NHL can be classified into more than 25 histological subtypes according to World Health Organization (WHO)

classification, and can be separated into aggressive (65% of NHL) and indolent forms (35%) (1). The Ann Arbor classification is used for staging, including 1–4 stages. Diffuse large B-cell NHL (DLBCL) is the most common type of aggressive NHL (31%), and follicular lymphoma (FL) the most common type of indolent NLH (22%). FL generally shows indolent progression with response to chemotherapy, but always relapses. Survival ranges from 5 to 15 years, depending on the Follicular Lymphoma International Prognostic Index (FLIPI) or Groupe d'Etude des Lymphomes Folliculaires (GELF) prognosis score. Prognosis of DLBCL is different, with 50–60% of patients being cured, with prognosis depending on the International Prognostic Index (IPI) score. Mantle cell lymphoma (MCL) represents 6% of NHL and has a poor overall survival (OS), with a median survival of about 5 years in young patients, but often lower survival rates in elderly patients. Treatment of disseminated NHL includes multi-agent chemotherapy, with the possibility of high-dose (HD) chemotherapy coupled with stem-cell transplantation (SCT) in high-risk young people (<60–65 years). In patients with aggressive or indolent B-NHL,

**Abbreviations:** ADCC, antibody-dependent cell-mediated cytotoxicity; ASCT, autologous stem-cell transplantation; BEAM, carmustine, etoposide, cytarabine, melphalan; CDC, complement-dependent cytotoxicity; CR, complete response; DLBCL, diffuse large B-cells NHL; DLT, dose-limiting toxicity; DR, duration of response; EFS, event-free survival; FDG-PET, positron emission tomography with ¹⁸F-fluorodeoxyglucose; FL, follicular lymphoma; FLIPI, follicular lymphoma international prognostic index; GELF, Groupe d'Etude des lymphomes folliculaires; HAMA, human anti-murine antibodies; HD, high-dose; HD, high-dose; IPI, international prognostic index; MAb, monoclonal antibodies; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; MRD, minimal residual disease; MRD, minimal residual disease; MTD, maximum tolerated dose; NHL, non-Hodgkin lymphoma; OR, objective response; OR, objective response; ORRs, overall response rates; OS, overall survival; PFS, progression-free survival; PR, partial response; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone; RIC, reduced-intensity conditioning; RIT, radioimmunotherapy; RIT-N, the international radioimmunotherapy network; SCT, stem-cell transplantation; TBI, total-body irradiation; TTP, time to progression; WHO, World Health Organization.

<footnote n="1">¹ Nuclear Medicine Department, University Hospital, Nantes, France</footnote>

<footnote n="2">² CRCNA, INSERM U892, CNRS UMR 7299, Université de Nantes, IRS-UN, Nantes, France</footnote>

<footnote n="3">³ Nuclear Medicine Department, ICO-Gauducheau, Saint-Herblain, France</footnote>

<footnote n="4">⁴ GIP ARRONAX, Saint-Herblain, France</footnote>
the introduction of rituximab (Mabthera®, Rituxan®, Roche Ltd., Genentech, Basel, Switzerland), a monoclonal chimeric anti-CD20 antibody, when combined with different chemotherapy regimens (R-chemotherapy) resulted in an improvement in patient outcome, compared with chemotherapy alone (2-4). Response rates with rituximab alone is rather modest (5). Involved-field radiation can be proposed for limited stage FL or treatment of residual masses of DLBCL.

Radioimmunotherapy (RIT) is a targeted therapy whereby irradiation from radionuclides is delivered to tumor targets using monoclonal antibodies (MAbs) directed to a tumor antigen (6, 7). NHL cells express well-characterized antigens, are highly radiosensitive, respond to cold mAbs, and represent a relevant indication for RIT. In 1988, DeNardo et al. reported the first RIT clinical trial in resistant NHL, using the anti-HLA-DR Lym-1 MAb labeled with iodine-131 (8). Over the last 20 years, RIT has significantly progressed with the development of new humanized mAbs, stable chelates for labeling, and pretargeting techniques (9). The cytotoxic mechanisms of RIT involve both radiobiological and immunological processes (10). MAbs, particularly rituximab, may exert cytotoxic effects through apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC). When MAbs are labeled with radionuclides, the combination of immunological and radiobiological cytotoxicity, including bystander effects, results in higher anti-tumor efficacy (10). RIT delivers continuous heterogeneous low-dose-rate irradiation (<1 Gy/h) concomitant with biological effects such as the repair of radiation-induced sublethal damage (10). Fowler evaluated the effects of low-dose-rate on the relative effectiveness of radiation as a function of the repair capacities of tissues using a mathematical model (11). They conclude that DNA repair lowers the efficacy of low-dose-rate irradiation, but that this effect may be overcome in part by cell cycle arrest in the G2/M phase, which makes cells more radiosensitive. However this hypothesis is now challenged by other explanations such as a decreased sensing of DNA damage by ATM at low-dose-rate that results in decreased activation of the early DNA damage response and repair (12). Other effect such as reoxygenation of hypoxic cells during the irradiation and effects on tumor vessels have been proposed to explain the relatively high efficacy of RIT (10). It is most likely that a combination of these effect and additional biological and immunological mechanisms are at work to make RIT effective in lymphoma, in spite of the low-dose-rate and low absorbed dose delivered by the therapeutic approach.

Although a dose-effect relationship has not yet been clearly demonstrated, it is likely to be present even if such a relationship could be masked by the anti-tumor effects of cold MAbs that are generally injected prior to the radiolabeled antibody. The choice of appropriate antibodies and radionuclide is critical (13). The path-length of penetration of the radioactive emission should match the size of the targeted tumor. Yttrium-90, with its long-range beta emission, is better suited for bulky disease. However, promising results have been observed using ⁹⁰Y-RIT in the consolidation setting in patients in partial response (PR) or complete response (CR) after induction therapy (14). Radionuclides such as ¹³¹I or ¹⁷⁷Lu with shorter-range energy emissions should be more favorable

in the setting of minimal residual disease (MRD). In this MRD clinical setting, biodistribution and tumor dosimetry are more favorable, tumor cells are less hypoxic and more radiosensitive (15), and immunotherapy is more efficient (16).

Today, two products targeting CD20 have been approved: ¹³¹I-tositumomab (Bexxar®; GlaxoSmithKline), and ⁹⁰Y-ibritumomab tiuxetan (Zevalin®, Spectrum Pharmaceuticals, Henderson, NV, USA). ¹³¹I-tositumomab is available in the United States, and ⁹⁰Y-ibritumomab is approved in Europe, the United States, Asia, and Africa. RIT can be integrated in clinical practice using non-ablative activities for treatment of patients with relapsed or refractory FL or as consolidation after induction chemotherapy in front-line treatment in FL patients. Different RIT protocols are assessed in clinical trials in FL or other lymphoma subtypes: myeloablative or HD treatment, RIT as consolidation after chemotherapy to target MRD, RIT in first-line treatment, fractionated RIT and other MAbs especially targeting antigens other than CD20. Moreover, personalized dosimetry protocols are proposed to better predict dose-effect relationships.

# RIT OF NHL IN CLINICAL PRACTICE

## ADMINISTRATION SCHEMES

Bexxar® and Zevalin® are administered 6-8 days after a pre-dose of cold MAb, respectively 2 × 450 mg of tositumomab and 2 × 250 mg of rituximab, to improve biodistribution and tumor targeting. The whole therapy requires only two outpatient visits. No dosimetry study is required for Zevalin®. When a dosimetry study is performed for research purposes, the first dose of cold MAb is injected with 5 mCi of ¹¹¹In-ibritumomab tiuxetan. The injected activity depends on body weight and platelet count. The therapeutic dose is 0.4 mCi/kg (14.8 MBq/kg) (0.3 mCi/kg, 11.1 MBq/kg, in patients with a platelet count of 100,000–149,000/mm³) to a maximum total activity of 32 mCi (1,184 MBq) (17). Bexxar® is delivered after a dosimetry study to identify patients whose biodistribution profiles preclude administration of the therapeutic step, and to adapt therapeutic activity to whole-body clearance of the radiolabeled MAb. Whole-body clearance is determined by a series of three scans recorded after infusion of 5 mCi of ¹³¹I-tositumomab. This dosimetry study allows determination of the injected therapeutic activity required to deliver a whole-body dose of 65–75 cGy. It has been demonstrated that if all patients had been injected with a standard dose of 40.7 MBq/kg, half of them would have been under or overdosed according to the whole-body clearance studies (18).

## EFFICACY

Despite the lack of phase III studies to clearly define the role of RIT in the management of B lymphoma in the era of rituximab-based therapy, RIT efficacy in B lymphoma has been demonstrated, with the likelihood of providing a durable response. In a study of 143 patients with relapsed or refractory FL or transformed B-cell NHL, Zevalin® appeared more efficient than rituximab, with the OR and CR rates significantly higher with Zevalin® (80 vs. 56%, *p* = 0.002, and 30 vs. 16%, respectively, *p* = 0.04) (87). Patients refractory to rituximab had a 74% OR and those with thrombocytopenia 83% OR (87, 19). Mean time to progression (TTP) in responders was 12.6 months. OR was observed in 50% of patients
with bulky lymphoma. Chemotherapy, administered in patients treated with RIT, was not associated with higher toxicity (20). In a meta-analysis involving relapsed NHL patients treated with Zevalin® in four clinical trials, long-term responses (TTP > 12 months) were seen in 37% of patients (21). At a median follow-up time of 53.5 months, the median TTP was 29.3 months. A third of these patients had been treated with at least three previous therapies, and 37% of them had not responded to their last therapy. The estimated 5 year-OS was 53% for all patients treated with Zevalin® and 81% for long-term responders.

Using Bexxar®, a long-term meta-analysis performed on 250 heavily pre-treated patients with indolent lymphoma treated in five clinical trials, OR rates ranged from 47 to 68% and CR rates from 20 to 38% (22). For the durable response population, the median duration of response was 45.8 months and the median duration of response had not been reached at 5 years for those who had achieved a CR. Interestingly, patients who showed durable responses had poor prognostic characteristics (bone marrow involvement in 41%, bulky disease ≥5 cm in 49%, and transformed histology in 23%).

In 2011 The International Radioimmunotherapy Network (RIT-N) reported on the long-term observational data from 467 Zevalin®-treated patients with an observation time of at least 12 months outside the randomized clinical studies (23). Lymphoma subtype was documented for all patients at initial diagnosis: 58% FL, 20% DLBCL, 14% MCL, and less than 10% other subtypes. Most patients had stage IV disease according to the Ann Arbor Classification, and 15% had bone marrow infiltration. FL patients received RIT as consolidation in 45% of cases, after first- and second-line therapy, and for recurrence in 37.7% of cases, in second- and more than third-line therapy. For patients with other lymphoma subtypes, RIT was predominantly used as consolidation (69%) in first-line therapy and in recurrence (13%) in second- and more than third-line therapy. Response was documented for 448 patients (260 with FL and 188 with other lymphoma subtypes). Three hundred and thirty-six (75%) patients achieved a CR and 70 (16%) a partial remission (PR). The CR rate in FL patients was 73%, as compared with 77% in other lymphoma subtypes. The difference in CR rates and progression-free survival (PFS) between the pivotal studies and the RIT-N study could be explained by a different patient selection, with treatment of patients earlier in clinical practice than in pivotal studies. Previously, Emmanouilides et al. showed that earlier injection of Zevalin® lead to better outcomes (24). As compared to patients treated at least at second relapse, patients treated at first relapse had a higher OR rate (86 vs. 72%, p = 0.051) and CR rate (49 vs. 28%, p = 0.004) and longer TTP (12.6 vs. 7.9 months, p = 0.038). Similarly, higher OR and CR rates were observed in patients treated by Bexxar® at first or second relapse (25).

In an interesting recent review on treatment of lymphoma by RIT, Illidge regretted the low implementation of RIT in current clinical practice (26). Despite the unique non-cross-reactive mechanisms of action of RIT with proven high clinical efficacy in patients resistant to chemotherapy and rituximab (probably the most active approaches ever developed for NHL), RIT has failed to be adopted by hemato-oncologists. Both ¹³¹I-tositumomab and ⁹⁰Y-ibritumomab have demonstrated high clinical efficacy in

heavily pre-treated populations, including patients with disease refractory to both chemotherapy and rituximab underlying their unique mechanisms of action of RIT.

## SAFETY

Hematological toxicity is the major side effect of RIT, and depends on bone marrow involvement and prior treatment (27–29). After a 0.4 mCi/kg of Zevalin®, grade-4 neutropenia, thrombocytopenia, and anemia occurred in 30, 10, and 3% of patients, respectively. Using Bexxar®, grade-4 neutropenia, thrombopenia, and anemia were observed in 17, 3, and 2%, respectively. Nadir occurred 7–9 weeks after Zevalin® injection, and 4–6 weeks after Bexxar® injection. In the long-term analysis of the international RIT-N, no significant difference was observed between patients with FL and patients with other lymphoma histologies (23). Time to complete recovery of blood count (hemoglobin > 12 g/dL, platelets > 150,000/µL, and leukocytes > 4,300/µL) had a median of 99 days for FL patients and 97 days for patients with other lymphoma subtypes. For hemoglobin, the nadir was reached in a median of 47.5 days for FL and 42 days for patients with other lymphoma subtypes, for platelets, in a median 35 days for FL and other lymphoma subtypes and for leukocytes, in a median of 40 days for FL and 38 days for patients with other lymphoma subtypes.

Non-hematological toxicity is generally low, including asthenia, anorexia, fever, nausea, headache, chills, arthralgia, and myalgia. Allergic reactions have been observed during MAb infusion, in particular after the first rituximab injection before Zevalin®. It is important to highlight that RIT is well tolerated by older patients and represents a strong treatment choice in this group of patients. Immunogenicity with human anti-mouse and human anti-chimeric antibody production was observed, ranging from 1 to 63% between studies. The immunogenicity risk was significantly higher in previously untreated patients (30).

Secondary myelodysplastic syndrome (MDS) or acute myelogenous leukemia were reported in 1–3% of cases (23, 27, 28, 31). The risk appears to be increased in patients previously treated by several lines of chemotherapy or radiotherapy. However, no causal relationship between RIT and subsequent MDS has been established, and there is ongoing debate about the role of prior therapy (i.e., fludarabine) as the causative agent rather than RIT itself (31). Moreover, prior RIT has not posed a limitation to subsequent stem-cell collection and transplantation (20, 32). A cytological and genetic analysis of bone marrow could be proposed for heavily pre-treated patients prior to beginning RIT. In the long-term analysis of the international RIT-N, the rate of secondary solid tumors was 0.8%, including breast cancer, prostate cancer, multiform glioblastoma, and non-small-cell lung cancer (23).

Finally, it is important to highlight that toxicity due to RIT is relatively low compared with the side-effects of anthracycline-based combination chemotherapy that includes significant early toxicity with vomiting, alopecia, neutropenia, infection, neuropathy, and late toxicity with cardiomyopathy, neuropathy.

## HIGH-DOSE TREATMENT

These approaches require autologous or allogeneic SCT and consist of injecting RIT myeloablative activity or a combination of standard or escalated activity of RIT with HD chemotherapy. The
rationale of HD approaches is to deliver curative radiation doses to tumor sites while limiting exposure to normal organs. The ratio- nale of RIT combined with chemotherapy is to obtain a synergistic effect between radio-sensitizing chemotherapy and radiation.

HD RIT

Administration of HD RIT without chemotherapy could be bene-
ficial in aggressive NHL, which probably requires higher absorbed
doses than indolent NHL, and for patients older than 60 years,
which are often denied potentially curative HD chemotherapy
because of the risk of excessive treatment-related morbidity and
mortality. Liu et al. reported results of RIT using activities of
10.4–29.0 GBq (280–785 mCi) of ¹³¹I-tositumomab in 29 patients
with relapsed B-cell NHL (33). The OR was 86%, with 79% CR
and, with a median follow-up of 42 months, the estimated OS and
PFS rates 68 and 42%, respectively. The non-hematopoietic dose-
limiting toxicity (DLT) was reversible cardiopulmonary insuffi-
ciency, which occurred in two patients at doses ≥27 Gy to the
lungs. Late side-effects included renal insufficiency in one patient,
and functional cardiac impairment in another. Two patients
developed second malignancies, but none have developed MDS.
In 2007, Gopal et al. reported their experience with HD ¹³¹I-
tositumomab activity in 24 patients older than 60 years with
relapsed B-cell NHL (34). About 12–42.7 GBq (328–1,154 mCi)
were injected to deliver 25–27 Gy to the critical normal organ
receiving the highest radiation dose. Autologous SCT was per-
formed approximately 2 weeks after therapy. The estimated 3 year
OS and PFS rates were 59 and 51%, respectively, with a median
follow-up of 2.9 years. There were no treatment-related deaths,
and only two patients experienced grade-4 non-hematological
toxicity.

Feasibility of HD Zevalin® (0.8–1.5 mCi/kg, 57–150 mCi, 2.1–5.55 GBq) was also reported in 13 refractory NHL patients (eight DLBCL, one FL, three MCL, and one transformed MZL) (35). Median age was 68 years (28–73), with a median of three prior therapy courses including HD chemotherapy (1–6). The dosimetry study showed acceptable calculated absorbed doses to normal organs. Two patients were treated at a lower activity level because of elevated liver uptake. Infections and liver toxicity were observed, but no pulmonary, cardiac or renal toxicity. About 8 of 13 patients showed objective response with six CR and two PR. One patient still in CR for MCL developed a MDS 2 years after treatment. Thus, HD RIT could be considered as an effective treatment modality for resistant/refractory NHL considered unsuitable for aggressive salvage treatments.

HD TREATMENT COMBINING RIT AND CHEMOTHERAPY

Regimens using escalated doses of RIT

Press et al. conducted a phase I/II trial to estimate the maxi-
mum tolerated dose (MTD) of ¹³¹I-tositumomab that could be
combined with etoposide and cyclophosphamide, followed by
autologous SCT, in 52 patients with relapsed B-cell NHL (36). The
MTD of ¹³¹I-tositumomab that could be safely combined with
60 mg/kg etoposide and 100 mg/kg cyclophosphamide was calcu-
lated to deliver 25 Gy to critical normal organs. The estimated OS
and PFS at 2 years was 83 and 68%, respectively. These findings
compare favorably with those in a non-randomized control group

of patients who underwent transplantation, external-beam total-body irradiation (TBR), and etoposide and cyclophosphamide therapy during the same period (OS of 53% and PFS of 36% at 2 years), even after adjustment for confounding variables in a multivariate analysis. Interestingly, survival was improved in aggressive and indolent NHL.

This approach was also validated in 16 patients with relapsed or refractory MCL (37). The enrolled patients had received a median of three prior treatments. The median activity of iodine-131 was 510 mCi (18.87 GBq). There were no therapy-related deaths. Among the 11 patients with conventionally measurable disease at the time of treatment, the respective CR and OR were 91 and 100%. Fifteen patients remained alive, and 12 without progression at 6–57 months after transplantation. OS at 3 years after transplantation was estimated at 93% and PFS at 61%.

Today, a standard HD schedule before transplantation includes
carmustine, etoposide, cytarabine, and melphalan (BEAM). Win-
ter et al. assessed a Z-BEAM regimen using escalated doses
of Zevalin® (900–1700 cGy to critical organs, 0.3–1.2 mCi/kg)
in 44 patients with chemo-refractory NHL (55% DLBCL, 16%
Richter, 16% MCL, 11% low-grade) (38). Two DLTs occurred at
the 1700 cGy dose level. One heavily pre-treated patient devel-
oped MDS 291 days after the treatment. The 3-year OS and PFS
rates were 52 and 37%, respectively. For dosimetry-based trials,
1500 cGy to the critical organ was the recommended dose (around
0.8 mCi/kg of Zevalin®). Outcomes were encouraging given the
high-risk patient population.

Regimens using standard doses of RIT combined with high-dose
chemotherapy

BEAM was also assessed when combined with standard dose of RIT. Vose et al. determined, in a phase I trial, the maximum outpatient dose of ¹³¹I-tositumomab (up to 0.75 Gy total-body dose) combined with BEAM followed by autologous SCT for the treatment of chemotherapy-resistant relapsed or refractory NHL (39). Twenty-three patients received 0.30–0.75 Gy total-body dose of RIT. The CR rate was 57% and the OR rate 65%. Short-term and long-term toxicities were similar to historical control patients treated with BEAM alone. With a median follow-up of 38 months (range, 27–60 months), OS was 55%, and event-free survival (EFS) 39%.

The combination of BEAM with standard dose of ⁹⁰Y-RIT has also been assessed. Shimoni et al. reported the safety and outcome following standard-dose Zevalin® (0.4 mCi/kg) followed by HD BEAM and autologous SCT in 23 patients (median age 55 years; ranging from 35 to 66) with chemo-refractory NHL (15 DLBCL, 7 Richter, 1 MCL), either primary refractory or in refractory relapse (40). Rituximab followed by Zevalin® were given on day-14 and HD BEAM started on day-6. Of the 21 patients evaluated, 11 achieved CR and 9 achieved PR, 5 of whom converted to CR with additional radiation therapy (overall CR rate 76%). The estimated 2 year OS and PFS were 67 and 52%, respectively. The day-100 rate of treatment-related mortality was 9% (95% CI, 2–33%), and the 2-year cumulative incidence of relapse was 31% (95% CI, 17–57%). Extensive prior therapy (>3 lines), high LDH and IPI score at ASCT, bulky disease, and progression during last chemotherapy were risk factors for reduced survival.
Krishnan et al. conducted another study combining Zevalin® with HD chemotherapy and autologous SCT using BEAM in patients with non-Hodgkin's lymphoma and who were considered ineligible for TBR because of older age or prior radiotherapy (41). Eligible patients had CD20 positive refractory FL (4), poor-risk MCL (13), DLBCL (20), or transformed lymphoma (4). Median age was 60 years (range, 19-78 years). With a median follow-up of 18.4 months, the global estimated 2 year-overall OS was 88.9% (89.7% for DLBCL, 84.6 for MCL, and 85% for FL, respectively). Adverse events were similar to those seen historically with HD BEAM alone. More recently and in order to compare RIT and TBR-based conditioning regimens of ASCT, Krishnan et al. conducted a matched-cohort analysis in 92 DLBCL patients treated with either Z-BEAM (0.4 mCi/kg of Zevalin) or TBI-based conditioning regimens (fractionated TBI at 1200 cGy, with etoposide and cyclophosphamide) (42). OS at 4 years was 81.0% for the Z-BEAM and 52.7% for the TBI group ($p=0.01$). There was no significant difference in the 4-year cumulative incidence of relapse/progression between Z-BEAM or TBI regimen (40.4 and 42.1%, respectively), whereas the non-relapse mortality was significantly higher in the TBI group (0% compared with 15.8% for TBI at 4 years), underlying the potentially lower toxicity of Z-BEAM.

In a recent prospective multicenter study, Shimoni et al. also demonstrated that standard-dose Zevalin® (0.4 mCi/kg) combined with BEAM HD chemotherapy was safe and possibly more effective than BEAM alone as a conditioning regimen for ASCT in 43 patients with relapsed/refractory aggressive non-Hodgkin lymphoma (31 DLBCL, three mediastinal lymphomas and nine transformed FL) (43). There was no difference in engraftment kinetics between the two study arms. There was no significant added toxicity with the Z-BEAM regimen although there was a trend for more mucositis and more serious infections in this group. The 2-year PFS was 59 and 37% in the Z-BEAM and BEAM arms, and the 2-year OS was 91 and 62%, respectively. Interestingly, multivariate analysis identified BEAM alone as one of the poor prognostic factors. The results of this randomized study confirmed all the previously reported observations that the addition of Zevalin® to HD chemotherapy is safe and not associated with excess toxicity. In order to definitively validate Z-BEAM regimen as a standard of care for ASCT, larger multicentric phase III clinical studies should be undertaken to better assess survival in homogenous groups of NHL patients, previously treated with rituximab-containing front-line and second-line chemotherapy.

## Regimens using standard doses of RIT combined with allogeneic SCT

Recently, reduced-intensity conditioning (RIC) regimens have been developed to permit elderly patients or patients with comorbidities, contraindicated for HD myeloablative chemotherapy, to allow allogeneic SCT. In order to increase the efficacy of the allogeneic graft, new strategies have been employed to increase the activity of RIC by adding Zevalin® in the conditioning regimen. Bethge et al. designed a study to evaluate the feasibility of adding RIT to allo-SCT (44). Forty patients with low-grade advanced NHL were enrolled in this phase 2 study combining RIT using standard dose of Zevalin® with RIC using fludarabine and 2 Gy TBI followed by allogeneic SCT. Combination of RIT with

RIC seemed not to increase the toxicity in comparison to the previous experience in patients conditioned with fludarabine/2 Gy TBI alone. The study concluded that combined use of RIT with RIC was feasible with acceptable toxicity, even in elderly and heavily pre-treated patients. Another study performed by Gopal et al. also examined the combined use of RIT with RIC (fludarabine and 2 Gy TBR) for a non-myeloablative allo-SCT (45). Dosimetry was studied on day-21 before standard dose of Zevalin®. Forty patients were included: 18 with indolent lymphoma, 14 with DLBCL (7 de novo and 7 aggressive transformations), and 8 with MCL. At a median follow-up of 30 months, the estimated 2 year OS and PFS were 54 and 31%, respectively. Multivariate analysis revealed that patients with aggressive histology had poor OS and PFS when compared with indolent histology ($p<0.01$). This prospective phase II trial concluded that the combined use of RIT with RIC was safe and feasible and was able to induce objective remissions in the majority of these high-risk patients, which were otherwise not previously considered candidates for either standard myeloablative or non-myeloablative transplantations, including patients with chemo-resistant, bulky disease, or aggressive histology.

## RIT AS CONSOLIDATION AFTER INDUCTION THERAPY

In the RIT-N analysis, a high efficacy in both FL and other lymphoma subtypes was observed when RIT was applied as part of the first-line treatment, as consolidation after induction therapy, to target MRD (23). The FIT randomized phase III trial showed the benefits of Zevalin® as consolidation in previously untreated FL patients (14). After completing induction therapy, patients were randomized to receive either standard dose of Zevalin® ($n=208$) or no further treatment ($n=206$). Induction therapies included CVP/COP ($n=106$), CHOP and CHOP-like ($n=183$), fludarabine combinations ($n=22$), chlorambucil ($n=39$), and rituximab-chemotherapy combinations ($n=59$). A high conversion rate from PR to CR of 77% was observed after RIT, leading to a high CR rate of 87% after RIT. Interestingly, the same CR rate was obtained after RIT in all subgroups of induction therapy, despite the difference in CR rate between the initial chemotherapy regimens. The quality of the response improvement was associated with increase of PFS of more than 2 years in the RIT-consolidation arm as compared to the control arm. However, no significant increase of PFS was observed in the sub-group of patients receiving a rituximab-based therapy as induction, probably because of the statistically small number of patients treated with this regimen. RIT could be considered as an alternative to rituximab for combination with CHOP. The Southwest Oncology Group (SWOG) and Cancer and Leukemia Group B recently reported the results of the phase III randomized intergroup protocol (SWOG S0016) that enrolled 554 patients with previously untreated, advanced-stage FL to compare six cycles of R-CHOP at 3 week intervals with six cycles of CHOP followed by consolidation with tositumomab/iodine I-131 tositumomab (46). However, no benefits were observed in the RIT arm: after a median follow-up period of 4.9 years, the 2-year estimated PFS was 76% on the CHOP-R arm and 80% on the CHOP-RIT arm ($p=0.11$), and the 2-year estimated OS 97% on the CHOP-R arm and 93% on the CHOP-RIT arm ($p=0.08$).
The fact that no benefit of RIT has been demonstrated as an alternative to rituximab combined with CHOP, or as consolidation after 6-8 cycles of R-CHOP, constitutes a limit in the development of RIT in an era in which R-CHOP has substantially improved outcome and represented a therapeutic standard. Moreover, rituximab maintenance treatment after R-chemotherapy was recently demonstrated to improve the relapse-free survival in a large phase III study (47). Several reports suggested comparable efficacy of RIT consolidation and rituximab maintenance; however these two approaches have not been compared in a randomized trial. Ideally, rituximab and RIT should be considered as complementary approaches with possible additive or synergistic effect. This could be achieved by performing a, randomized phase III trials to compare maintenance by rituximab versus consolidation by RIT or maintenance by rituximab versus consolidation by RIT+ maintenance by rituximab, following induction with R-CHOP.

The use of RIT as consolidation might also allow reduced chemotherapy cycle number. Leonard et al. reported in 2005, in 35 previously untreated FL patients, the efficacy of three abbreviated courses of fludarabine followed by, 6–8 weeks later, tositumomab and ¹³¹I-tositumomab (48). After fludarabine, 31 (89%) of 35 patients responded, with three (9%) of 31 patients achieving a CR. After the full regimen of fludarabine and ¹³¹I-tositumomab, all 35 patients responded, with 30 patients (86%) achieving a CR. The 5-year estimated PFS rate was 60%. Baseline FLIPI was significantly associated ($p = 0.003$) with PFS. About 10 of 13 patients (77%) with baseline bone marrow Bcl-2 positivity demonstrated molecular remissions at 12 months. Toxicities were manageable and mainly hematological. Two of 35 patients (6%) developed human anti-murine antibodies (HAMA) after RIT. The authors concluded that this sequential treatment regimen was highly effective as a front-line therapy for FL, particularly for low- or intermediate-risk FLIPI patients. Zevalin® also has been assessed as consolidation after Rituximab with short duration chemotherapy (49). Forty-one patients with previously untreated FL received rituximab for four consecutive weeks, followed by three cycles of rituximab combined with either CHOP (88%) or CVP (cyclophosphamide/vincristine/prednisone; 12%). To complete treatment, all patients received Zevalin® 4–6 weeks after the final dose of chemotherapy. After completion of short-course rituximab/chemotherapy, 95% had objective responses, with 30% clinical CR. The clinical CR rate increased to 72% following RIT. After a median follow-up of 67 months, the estimated 5 year PFS and OS rates were 64 and 96%, respectively. Zevalin® was well tolerated after short-course rituximab/chemotherapy and the authors concluded that a high CR rate and a long PFS were obtained using this scheme. Definitive demonstration of improved efficacy versus rituximab/chemotherapy alone requires a randomized study.

Radioimmunotherapy consolidation has been also assessed in other B-NHL subtypes and represents an especially relevant therapeutic alternative in elderly patients. In DLBCL patients, although the R-CHOP combination as standard regimen has led to improved outcomes, there is a group of poor-risk patients with a lower chance of being cured with standard R-CHOP, thus needing an alternative treatment strategy. Zinzani et al. published in 2010 the results of a phase II study assessing the efficacy and safety

of Zevalin® following four cycles of R-CHOP21, in 55 high-risk elderly (age ≥ 60 years) patients with previously untreated DLBCL (50). Forty-eight of the 55 patients received RIT. The OR rate for the entire treatment regimen was 80%, including 73% CR. About 8 of the 16 patients (50%) who achieved less than a CR after R-CHOP improved their remission status after RIT. With a median follow-up of 18 months, the 2-year PFS was estimated to be 85%, with a 2-year OS of 86%. RIT toxicity was relatively high, consisting of grade 3–4 neutropenia in 23 patients and thrombocytopenia in 15 patients. These results suggested that RIT could be considered as a promising alternative approach in high-risk elderly patients who are not candidates to SCT.

Recently, Smith et al. reported the results of a Phase II study of the Eastern Cooperative Oncology Group Study assessing R-CHOP in untreated MCL patients (51). The rational was based on three points: (a) MCL is predominantly a disease of patients older than 60 years of age, very often contraindicated for HD chemotherapy, (b) R-CHOP as initial therapy for untreated MCL had a high response rate, but remissions are not durable, and (c) RIT of MCL seemed to induce a high response rate but very short TTP (52). About 56 patients were eligible: 48 patients were treated with Zevalin® standard dose whereas three received a 25% reduced-dose. The design required 52 eligible patients to detect a 50% improvement in the median time to treatment failure compared with that reported for six cycles of R-CHOP. For the 56 analyzed patients the overall response rate at completion of therapy was 82%: RIT improved quality of response in 22 patients: 16 patients converted from PR to CR/CRu, three patients from stable disease to CR/CRu, and three patients from stable disease to PR. With a median follow-up of 72 months, the median time to treatment failure was 34.2 months and the estimated 1.5 year time to treatment failure 69%. These results were better than those previously reported in patients treated by six cycles of R-CHOP and there was no unexpected toxicity after RIT.

Even if the potential of RIT as consolidation after R-CHOP induction therapy were to be confirmed in randomized large phase III studies, these different studies suggest that RIT is a relevant option as consolidation therapy in different subtypes of B-NHL, in order to decrease the number of chemotherapy courses in elderly patients or as an alternative of STC in high-risk patients.

## RIT MONOTHERAPY IN FIRST-LINE TREATMENT

Radioimmunotherapy can also be considered alone in front-line treatment. As shown by Emmanouilides et al., an injection of Zevalin® earlier in the course of the disease leads to better outcomes (24). Indeed, the best results of non-myeloablative RIT administered alone (without chemotherapy) have been obtained as first-line treatment of FL (30). A single 1 week course of ¹³¹I-tositumomab therapy, as initial treatment, can induce prolonged clinical and molecular remissions. Seventy-six patients with stage III or IV FL received as initial therapy a single course of ¹³¹I-tositumomab therapy. Ninety-five percent of the patients responded, including 75% with a CR. The use of PCR to detect rearrangement of the bcl2 gene showed molecular responses in 80% of assessable patients who had a clinical CR. After a median follow-up of 5.1 years, the actuarial 5 year PFS for all patients was 59%, with a median PFS of 6.1 years. Of 57 patients who had a CR,
40 remained in remission for 4.3–7.7 years. Hematological toxicity was moderate, with no patient requiring transfusions or growth factors. No case of MDS has been observed. The immunization rate was higher than the rate observed in patients treated later in the course of disease.

Preliminary results of a European multicenter study using fractionated RIT Zevalin® as a front-line therapy for patients with FL grade I–IIIa with at least one criteria of high tumor burden or B symptoms were presented at The American Society of Hematology in 2011 (53). Treatment consisted of two doses of Zevalin® (11.1 MBq/kg) given 8–12 weeks apart. Patients with greater than 20% bone marrow involvement with lymphoma received four weekly infusions of Rituximab (375 mg/m²) and proceeded to fractionated RIT only if a repeat bone marrow biopsy demonstrated clearing of lymphoma with less than or equal to 20% involvement. 74 patients with a median age of 61 years (28–80), including 58 with stage III–IV disease were included. About 55 patients received the two-planned Zevalin® infusion whereas 17 received only one infusion. At a median follow-up of 1.52 years (range 0.13–3.69 years) the PFS was 67%, 20/74 patients had progressed. The ORR was 97.1% with 64% of CR/CRu. The most common toxicity was hematologic and reversible. One case of MDS was diagnosed 26 months after treatment.

Recently, Scholz et al. also evaluated, in an international multicenter phase II clinical trial, the efficacy, and feasibility of Zevalin® as first-line treatment for FL (54). Fifty-nine patients, median age 66 years (range, 51–83 years), were included. Treatment indication resulted from B symptoms, grade 3a, organ compression or infiltration, rapid growth and/or bulky disease. The ORR at 6 months after RIT was 87%, with 41% of the patients achieving CR, 15% CRu, and 31% PR. Median PFS was 25.9 months (95% CI, 18.2–33.7 months). RIT was well tolerated and the most common toxicity was hematologic and reversible. Patients with increased LDH may not benefit from RIT as much as patients with normal LDH do.

In these two studies assessing monotherapy with Zevalin® in first-line treatment, the OR was superior to the response rate reported in chemotherapy-naive patients treated with four courses of rituximab monotherapy. Ghielmini et al. reported in this population a 67% response rate with only 9% CR in 64 patients receiving four courses of rituximab (55). RIT should be considered as an attractive therapeutic option in elderly patients or in patients with comorbidity.

## FRACTIONATED RIT

The advantages of fractionated delivery of external radiation therapy may also apply to RIT (85). RIT produces a less uniform tumor dose distribution than external radiation therapy, because of the inability of MAbs to penetrate uniformly throughout the tumor, resulting in some tumor regions under-dosed. An absorbed dose heterogeneity ranging up to 400% was measured using quantitative autoradiography, in the Raji B-cell lymphoma animal model injected with anti-HLA-DR<sup>131</sup>I-Lym-1 MAb (56). DeNardo et al. reported the following advantages for fractionated RIT: more uniform MAb distribution and radiation dose, patient-specific radionuclide and radiation dose, control toxicity by titration of an individual patient, reduced toxicity, increased

injected activity, tumor radiation and efficacy, and prolongation of tumor response (57).

Several clinical studies have shown the benefits of fractionated RIT in patients with B-cell hemopathies. DeNardo et al. reported toxicity and efficacy of <sup>131</sup>I-Lym-1 in 25 patients with relapsing NHL and five patients with chronic lymphocytic leukemia (58): 19/25 NHL patients had bone marrow involvement, with extensive marrow malignancy in seven cases, and all five patients with CLL had diffuse bone marrow infiltration. Patients were treated with doses of 30 or 60 mCi of <sup>131</sup>I-Lym-1, 2–6 weeks apart; 11 of the 30 patients completed the intended 300 mCi. Treatment was interrupted by hematological toxicity in three patients and the development of HAMA in three; a 57% response rate was obtained. Based on this strategy, a dose escalation trial was designed to define the MTD of the first two of a maximum of four injections of <sup>131</sup>I-Lym-1 given 4 weeks apart (58). <sup>131</sup>I-Lym-1 was escalated from 40 to 100 mCi/m². The non-myeloablative MTD for each of two doses of <sup>131</sup>I-Lym-1 was 100 mCi/m² in patients with less than 25% bone marrow involvement. All three entries in this patient cohort achieved CR.

The use of chimeric or humanized MAbs facilitates fractionation by reducing the immunization rate. Illidge et al. published the results of a protocol assessing four weekly infusions of 375 mg/m² rituximab, followed by two fractions of <sup>131</sup>I-rituximab, preceded by a 100-mg/m² predose of rituximab, in relapsed indolent NHL (59). Induction therapy with rituximab significantly increased the effective half-life of <sup>131</sup>I-rituximab, and high serum levels of rituximab after induction therapy correlated with increased effective half-life of the radiolabeled MAb. The pharmacokinetics of rituximab have previously been studied and found to be influenced by the availability of CD20 (the “antigen sink”), with the greater number of CD20-binding sites in bulky disease causing sequestration of rituximab and decreasing concentrations in the serum compartment. A negative correlation was observed between splenic and lymph node volumes and the rituximab serum levels after initial rituximab dosing. Interestingly, patients with large initial tumor burdens exhibited a greater than 40% increase in <sup>131</sup>I-rituximab’s effective half-life between delivery of the first and the second fractions. The most likely explanation for these observations was the tumor responses observed clinically after the first therapeutic injection. The OR rate was 94%, with 50% CR. The median TTP was 20 months, significantly longer than for the last chemotherapy course. Moreover, fractionated <sup>131</sup>I-rituximab provided cumulative whole-body doses of more than 120 cGy, approximately 60% greater than those obtained previously after a single course of RIT, without significant hematologic toxicity. These results demonstrated the high potential of fractionated injections for increasing RIT efficacy for NHL treatment.

## PRETARGETED RIT OF LYMPHOMA

Because of the long residence time of antibodies in the circulation and their efficient transfer to bone marrow, the DLT in RIT is hematological in most cases. The pretargeting approach that uses a low molecular weight as a carrier for radioactivity and unlabeled antibody conjugates, injected in advance, to target the radioactivity to tumors was geared at reducing non-tumor tissue exposure (60). Pretargeting may be achieved using a variety of methods. Two of
them have been documented in large numbers of preclinical and clinical studies. One uses bispecific anti-tumor/anti-hapten antibodies to target low molecular weight radiolabeled haptens. The other uses antibody-avidin conjugates to target radiolabeled biotin derivatives. In both cases, improvements have been necessary to prevent excess circulating antibody conjugates to trap the radiolabeled molecule in the circulation. Antibody-avidin pretargeting thus generally includes a chase step before injection of the radiolabeled biotin derivative, while bispecific antibody pretargeting uses bivalent haptens that bind more tightly to bispecific antibody molecules attached to the target cell surface than to the excess bispecific antibody present in the circulation (60). With both approaches, tumor to non-tumor target activity uptake ratios are improved as compared to directly labeled antibodies and pretargeting was shown to be able to deliver tumoricidal irradiation doses. The feasibility of pretargeting in the clinic has been documented in several instances and it has been shown that it can increase OS in progressive, metastatic medullary thyroid carcinoma, a radioresistant and chemo-resistant solid tumor (61).

For lymphoma, and more generally in hematological diseases, it is believed that tumor cells are more readily accessible to radiolabeled antibodies and often more radiosensitive and, as a result, that sophisticated targeting approaches such as pretargeting are not required to achieve tumor control. Indeed, even though pre-targeting approaches to lymphoma were proposed a long time ago in mice (62, 63), the literature remains poor in terms of reports of pretargeted RIT clinical trials of lymphoma. In one study of 10 patients with relapsed or refractory B-cell NHL, seven were treated with a streptavidin-conjugated anti-CD20 antibody (rituximab) to sequester yttrium-90-labeled DOTA-biotin (1.11 or 1.85 GBq/m²) after clearing excess streptavidin conjugate by an injection of biotin-N-acetyl-galactosamine (64). Radiolabeled biotin was shown to localize in the tumor, with rapid excretion of unbound radioactivity. Little non-hematologic toxicity was observed and hematological toxicity was limited and transient. Three complete and one PR were observed. However, humoral immune responses to streptavidin were demonstrated in 6 of 10 patients. In another phase I trial, a tetrameric single-chain anti-CD20-streptavidin fusion protein was used to target yttrium-90-labeled DOTA-biotin in NHL patients, again with a clearing step (65). In this study, the 15 patients received only 560 MBq/m² of ⁹⁰Y-DOTA-biotin that rapidly localized in tumor or was excreted in the urine. There were two complete remissions (90 and 325 days) and one PR (297 days) and hematologic toxicity was acceptable. However, patient immune responses against the antibody-streptavidin conjugate was frequent.

It is clear that the remarkable efficacy of directly labeled antibodies against lymphoma makes pretargeting less attractive here than in solid tumors. However, pretargeting could make activity escalation possible and could in principle achieve very high response rates without bone marrow ablation, as more recent preclinical studies suggest (66). Another perspective created by pretargeting is the possibility of using short-lived alpha-emitting radionuclides in consolidation therapy to eradicate MRD because of the fast tumor activity accretion provided by this technology (67).

## TARGET ANTIGENS OTHER THAN CD20

The development of a RIT approaches against antigens other than CD20 targeted by rituximab appears relevant, especially if RIT is applied in combination with rituximab-based therapy, offering the possibility of targeting populations of cells not expressing CD20, or not responding to anti-CD20 cold MAbs. Several antigens have been tested: CD21, CD22, CD37, and HLA DR (68). Both radiolabeled anti-CD22 epratuzumab and anti-HLA-DR (Lym-1) MAb have shown efficacy in patients who have failed chemotherapy, either with low-grade or aggressive forms of NHL (58, 60, 69). CD22 is a transmembrane glycoprotein expressed on mature B-cells but not expressed on stem cells or plasma cells, and functions in B-cell regulation/activation. CD22 is highly expressed across malignant B-cell histologies. Epratuzumab, has good features for RIT because it is humanized, internalized by target cells, stably labeled using DOTA (1,4,7,10-tetraazacyclododecanyl, N',N'',N''-tetraacetic acid), and administered without a loading dose of cold antibody, at variance with Zevalin® or Bexxar®.

Sharkey et al. reported the results of a phase I/II trial assessing ⁹⁰Y-epratuzumab in patients with relapsing B lymphoma (70). Patients had a pre-therapy imaging study with ¹¹¹In-epratuzumab 1 week before ⁹⁰Y-epratuzumab injection, starting at an activity level of 0.185 GBq/m² in patients who had prior HD chemotherapy (Group 2), and at 0.370 GBq/m² in patients who did not have a prior stem-cell transplantation (SCT) (Group 1), with escalation in 0.185 GBq/m² increments. Radiation absorbed doses to liver, lungs, and kidneys averaged 0.55 ± 0.13, 0.28 ± 0.06, and 0.38 ± 0.07 mGy/MBq, respectively, with 0.14 ± 0.02 and 0.23 ± 0.04 mGy/MBq delivered to the whole-body and red marrow, respectively. Tumor doses ranged from 1.0 to 83 mGy/MBq for a 0.5-g lesion (median = 7.15 mGy/MBq). Anti-tumor effects were seen in both indolent and aggressive NHL. The data also suggest that anti-tumor responses of potentially equal magnitude can occur irrespective of tumor targeting and tumor size. Hence, tumor response did not correlate with the radiation dose delivered or with the tumor being visualized by external imaging. These observations should not been interpreted that there was a minor effect of targeting, but probably could be explained by the role of immunological mechanisms in tumor response after RIT. In this study, an immunization was detected in only two of 16 patients.

After demonstrating, in a single-center trial, the safety and preliminary efficacy of ⁹⁰Y-epratuzumab administered at low 5 mCi/m² (185 MBq/m²) doses repeated over several weeks (71), a multicenter phase I/II study was designed to assess fractionated ⁹⁰Y-epratuzumab in NHL relapsing patients (72). Unlabeled epratuzumab was co-administered each week for a 1.5 mg/kg protein dose. The first week, ¹¹¹In-epratuzumab was co-infused, with targeting of at least one known disease site by gamma-camera imaging 3–6 days later required to continue weekly ⁹⁰Y-epratuzumab infusions. Patients with prior SCT underwent separate dose escalation, starting with 92.5 MBq/m² weekly doses escalated in 2.5 mCi/m² increments. Non-SCT patients started with 185 MBq/m² weekly doses and 2.5 mCi/m² increments that increased to 5.0 mCi/m² to reach the highest dose level. Sixty-four patients (32 males, 32 females) were enrolled at five institutions in France and Germany between 2001 and 2007, including
35 FLs, 14 MCL, 11 DLBCL, and four patients with marginal zone lymphoma. These patients had one to five prior therapies (median: 2), including an anti-CD20-based therapy in 52 cases and a bone marrow transplant in 17 cases. The total ⁹⁰Y treatment dose ranged from 0.185 to 1.665 GBq/m², with comparable numbers treated at ≤0.37 (N = 17), >0.37–0.74 (N = 13), >0.74–1.11 (N = 16), and >1.11 GBq/m² (N = 18). Even at the highest total ⁹⁰Y dose of 1.665 MBq/m² studied, grade 3–4 hematological toxicities were manageable with support in patients with <25% bone marrow involvement, and transient with 2–3 weeks median recovery to Grade 1. The overall OR rate was 62% (48% CR/CRu), including all NHL subtypes [FL: 74% (62%); MCL: 50% (21%); DLBCL: 30% (20%); marginal zone: 100% (100%)]; and in poor-risk patients [unresponsive to last therapy: 72% (56%); bulky disease: 60% (35%); elevated LDH: 56% (44%); positive bone marrow: 46% (31%); prior SCT: 41% (29%)]. For FL without prior SCT, response rates increased with total ⁹⁰Y dose, with 92% CR/CRu at the highest dose levels (>1.11 MBq/m²). Patients with CR/CRu achieved long-lived responses continuing up to 5 years, including 24.6 month median PFS for 12 FL patients receiving >1.11 MBq/m² total ⁹⁰Y dose. This study demonstrated that fractionated RIT with ⁹⁰Y-epratuzumab achieved high rates of durable CRs with manageable toxicity in previously treated lymphoma patients. While fractionation may have improved the diffusion of subsequent doses, the favorable efficacy and safety observed here even at HDs also could reflect antibody internalization with improved ⁹⁰Y residence time, the more stable DOTA radio-labeling method used, or the lack of neutralizing antibodies induced with this humanized antibody.

Targeting of antigens other than CD20 appears particularly interesting in the context of consolidation therapy after rituximab-based therapy and the high injected activity achieved with fractionated ⁹⁰Y-epratuzumab suggested the benefits of using this approach in DLBCL probably requiring higher dose than indolent lymphoma. A French phase II trial sponsored by the LYSA group assessed front-line treatment using fractionated RIT with ⁹⁰Y-epratuzumab as consolidation therapy after courses of R-CHOP in previously untreated elderly (age >60 years) patients presenting with stage I/II bulky or stage III/IV DLBCL. Two infusions of ⁹⁰Y-epratuzumab (2 × 555 MBq/m², 7 days apart) were delivered 8 weeks after R-CHOP (73). Seventy-five patients have been accrued prospectively, 57 (76.0%) with Ann Arbor stage III/IV disease; 61/75 (81.2%) received the RIT. RIT toxicity consisted of grade 3–4 hematologic toxicity in 51/61 patients (83.6%). RIT's severe non-hematologic toxicity consisted of grade-4 gastrointestinal in one patient (1.6%) and grade-4 infection in three (4.9%). Two patients (2.6%) developed MDS 5–20 months after RIT. The OR rate after 6 × R-CHOP14 was 94.6% (71/75); 52 patients (69.3%) achieved CR/CRu and 19 (25.3%) had a PR. In an intention-to-treat analysis, CR/CRu rate after 6 × R-CHOP14 followed by RIT was 72.0% (N = 54). At a median follow-up of 24 months (range 1–46), 18 patients experienced lymphoma progression and/or a related death, yielding an estimated 2 year EFS of 73.3% (60.7–82.5%) and an estimated 2 year OS of 83.2% (71.4–90.4%). For the 61 patients who received six courses of R-CHOP followed by ⁹⁰Y-epratuzumab, ORR was 91.8% (56/61), 50 patients (81.9%) achieving CR/CRu. This phase II study clearly shows

that fractionated RIT with ⁹⁰Y-epratuzumab as a consolidation therapy after 6 × R-CHOP14 is feasible and tolerable in elderly untreated DLBCL patients with advanced disease. RIT improved response status observed after 6 × R-CHOP14. EFS data achieved with R-CHOP plus RIT compare favorably with those achieved with R-CHOP alone in the same patient population.

Another important perspective is the clinical evaluation of dual-targeted antibody/radioantibody therapy (74, 75). Combining an unconjugated anti-CD20 antibody therapy with a radioimmunoconjugate binding to a non-competing antigen might improve responses by allowing optimal uptake of each agent. Mattes et al. showed in an animal model the benefit of targeting a non-competing antigen for consolidation after RIT using ⁹⁰Y-epratuzumab tetraxetan. Tumor response and survival rates were improved when a consolidation using anti-CD20 veltuzumab was delivered after anti-CD22 RIT (74). Moreover, Sharkey et al. (75) demonstrated that injection of cold MAbs after the radioactivity dose provided higher efficacy than injection before RIT, and that the amount of predose of cold MAbs should be minimized.

These preclinical data raise important questions, and a re-examination of RIT in the treatment of NHL was proposed by R. Sharkey, O. Press and D. Goldenberg in Blood in 2009 (86). The authors emphasized that in RIT clinical practice, nearly 900 mg of unlabeled anti-CD20 IgG antibody is predosed to the patient before the anti-CD20 ⁹⁰Y or ¹³¹I RIT. Combining a naked anti-CD20 therapy with a radioimmunoconjugate binding to a non-competing antigen might improve responses by allowing optimal uptake of each agent. Preclinical models indicated that careful consideration should be given to predosing when using competing antibodies, but that consolidation anti-CD20 therapy enhances the efficacy of radioimmunoconjugate therapy.

## OPTIMIZATION OF INJECTED ACTIVITY USING DOSIMETRY

Pre-RIT dosimetry studies should allow the pharmacokinetics of each patient to be assessed and allow the injected activity to be adapted. Dosimetry studies performed before Bexxar® injection showed large variability between patients, requiring injection of around 1.85–5.55 GBq of Bexxar® to deliver a 75 cGy whole-body dose. Indeed, many patients are probably under-treated with the standard activity of 14.8 MBq/kg of Zevalin®. No dose-effect relationship has been clearly demonstrated in clinical studies, but patients had been heavily pre-treated. Dosimetry of RIT in first-line treatment should allow a better analysis of a dose-effect relationship.

Moreover, immuno-PET using iodine-124 or yttrium-86 could improve quantitative imaging and biodistribution analysis of Bexxar® and Zevalin®, respectively. Preclinical studies in mice showed that ⁸⁹Zr- and ⁸⁸Y-Zevalin® had a very similar biodistribution, implying that ⁸⁹Zr-Zevalin®-PET might be well suited for prediction of ⁹⁰Y-Zevalin® biodistribution in a myeloablative setting (76).

In principle, dosimetry is useful to optimize radiation delivery during treatment in order to avoid toxicities to critical organs and to administer absorbed doses to tumors as highly as possible. Although firmly established in external radiotherapy treatment, this paradigm is not yet so settled in RIT. In NHL RIT, dosimetry studies are performed more to avoid hematological toxicities
rather than to estimate absorbed doses to targets, which are usu-
ally disseminated throughout the patient and often of small sizes,
particularly in residual diseases (77).

Dosimetry studies are mandatory with Bexxar® treatments.
Indeed, Wahl et al. showed that pharmacokinetics varied widely
from one patient to another and more importantly that bone mar-
row toxicities were correlated to the total-body radiation dose (78).
In contrast, no dosimetry study is required for Zevalin® treatment
as no toxicity/absorbed dose relationship was assessed during the
initial multicenter study (79).

Since then, recent publications have described better toxic-
ity/absorbed dose relationships. In a series of 58 FL patients treated
by Zevalin® RIT as a consolidation therapy after a first-line ther-
apy, Delaloye et al. conducted a dosimetry study, assessing bone
marrow absorbed dose using blood samples (80). The authors
clearly found a correlation between whole-body and bone marrow
absorbed doses with the PFS whereas no correlation was estab-
lished between both absorbed doses and hematological toxicity.
It is worth noticing that RIT was employed at an early stage of
the therapeutic course as opposed to the initial phase I/II study
where patients were heavily treated beforehand and probably suffer-
fed from major bone marrow impairments. This suggests that
the sooner RIT is positioned along the therapeutic course, the
better it is to assess an absorbed dose/effect relationship.

This assumption was also supported by a recent dosimetry
study performed on 28 newly diagnosed FL patients treated by two
fractions of Zevalin® (81). Different bone marrow absorbed dose
calculation approaches were compared to hematological toxicity.
One main result was that blood samples were not able to predict
hematological toxicities on patients even with low BM involvement
(<20%) as opposed to image-based methods that clearly foresaw
those toxicities. Another interesting result was that quantification
based on 3D SPECT imaging afforded a better relationship than
2D whole-body imaging and echoed findings of He et al. (82).
Indeed, in this last publication, 2D whole-body and SPECT imag-
ing were also compared on 18 patients enrolled in clinical trial
of HD myeloablative Zevalin® therapy. The authors showed dif-
ferences in residence time as high as 18% for the dose-limiting
organ – the liver in this context.

This stresses an interesting point previously mentioned by
Sjögreen-Gleisner et al. (83). In this recent review of lymphoma

RIT dosimetry, the authors compared dosimetry results in light
of the approaches used in different publications and concluded
that there was a definite influence due to the dosimetry method-
ology used. This is not surprising of course, but does highlight
the importance of standardization of dosimetry procedures, and
advocates for the more widespread use of 3D SPECT/CT imaging
which will lead to the more robust approach.

As already mentioned, a much more challenging task and
goal would be to correlate tumor absorbed dose to therapeutic
response. Dewaraja et al. also used SPECT/CT imaging to per-
form a dosimetry study on 20 NHL patients treated with Bexxar®
RIT (84). They found an improved tumor absorbed dose-response
relationship once an equivalent uniform dose (EUB) that takes
into account the biological effect of the cold antibody was con-
sidered. Publications showing absorbed dose-response/toxicity
relationships are currently present even in NHL RIT therapy. In
this context, dosimetry should be performed with a high qual-
ity level in order to demonstrate a correlation between absorbed
dose-effect/toxicity relationships.

CONCLUSION

Clinical results show that RIT has significant efficacy, but moder-
ate response duration as a monotherapy in rituximab-refractory
recurrence of NHL. A higher therapeutic impact may be achieved
using RIT in HD myeloablative treatment, as consolidation after
chemotherapy-immunotherapy, or as a first-line treatment. Ran-
domized phase III clinical trials should be performed in naïve
or minimally treated patients to better identify the benefits and
the role of RIT in NHL in the era of rituximab based therapy.
Dosimetry studies and fractionated administration could probably
optimize the injected activity. Preclinical studies suggest the ben-
efits of dual-targeted antibody/radioantibody therapy, combining
an unconjugated anti-CD20 antibody therapy with a radioim-
munoconjugate binding to a non-competing antigen, such as
CD22.

ACKNOWLEDGMENTS

This work has been in part supported by a grant from the French
National Agency for Research called “Investissements d’Avenir” n°
ANR-11-LABX-0018-01 and by a grant from the Pays de la Loire
Regional Council called “NucSan.”

REFERENCES

1. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organisation classification of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting. *Airlie House, Virginia, November* 1997. *J Clin Oncol* (1999) **17**:3835–49.

2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N Engl J Med* (2002) **346**:235–42.

346:235-42. doi:10.1056/NEJ
Moa011795

3. Coiffier B, Reyes F. Groupe d'étude des lymphomes de l'adulte. best treatment of aggressive non-Hodgkin's lymphoma: a French perspective. *Oncology* (2005) **19**:7–15.

4. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular

lymphoma compared with
therapy with CHOP alone: results
of a prospective randomized
study of the German Low-Grade
Lymphoma Study Group. Blood
(2005) **106**:3725–32.

5. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. *J Clin Oncol* (2002) **20**:3262–9. doi:10.1200/JCO.2002.11.076

6. Chatal JF, Mahé M. Therapeutic use of radiolabelled antibodies. In: Murray IPC, Ell PJ editors. *Nuclear*

Medicine in Clinical Diagnosis and
Treatment. Edinburgh: Churchill
Livingstone (1998). p. 1101–14.

7. Barbet J, Bardiès M, Bourgeois M, Chatal JF, Chérel M, Davodeau F, et al. Radiolabeled antibodies for cancer imaging and therapy. *Methods Mol Biol* (2012) **907**:681–97. doi:10.1007/978-1-61779-974-7_38

8. DeNardo GL, DeNardo SJ, Lam-
born KR, Goldstein DS, Levy NB,
Lewis JP, et al. Pilot studies of
radioimmunotherapy of B cell
lymphoma and leukemia using I-
131 lym-1 monoclonal antibody.
*Antib Immunoconjug Radiopharm*
(1988) 1:17–33.
9. Goldenberg DM, Sharkey RM. Recent progress in cancer therapy with radiolabeled monoclonal antibodies. *Ther Deliv* (2011) **2**:675-9. doi:10.4155/tde.11.44

10. Pouget JP, Navarro-Teulon I, Bardiés M, Chouin N, Cartron G, Pèlegrin A, et al. Clinical radioimmunotherapy – the role of radiobiology. *Nat Rev Clin Oncol* (2011) **8**:720–34. doi:10.1038/nrclinonc.2011.160

11. Fowler JF. Radiobiological aspects of low dose rates in radioimmunotherapy. *Int J Radiat Oncol Biol Phys* (1990) **18**:1261-9. doi:10.1016/0360-3016(90)90467-X

12. Sgouros G, Knox SJ, Joiner MC, Morgan WF, Kassis AI. MIRD continuing education: bystander and low dose-rate effects: are these relevant to radionuclide therapy? *J Nucl Med* (2007) **48**:1683-91. doi:10.2967/jnumed.105.02813

13. Barbet J, Chatal JF. The best radionuclide for radioimmunotherapy of small tumors: beta- or alpha-emitter? *Eur J Nucl Med Mol Imaging* (2011) **38**:271-3. doi:10.1007/s00259-010-1707-7

14. Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. *J Clin Oncol* (2008) **26**:5156-64. doi:10.1200/JCO.2008.17.205

15. Brown JM, Giacca AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. *Cancer Res* (1998) **58**:1408-16.

16. Collins-Burow B, Santos ES. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma. *Expert Rev Anti-cancer Ther* (2007) **7**:257-73. doi:10.1586/1473714.07.3.257

17. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD 20⁺ B-cell non-Hodgkin's lymphoma. *J Clin Oncol* (1999) **17**:3793-803.

18. Zelenetz AD, Wahl R, Leonard JP, Gregory SA, Clapp K, Kaminski M. Individualized patient dosing with radioimmunotherapy prevents under- and overdosing of patients and is associated with tolerable and predictable hematologic toxicity in patients with non-Hodgkins lymphoma (NHL). *Blood* (2001) **98**:134a-5.

19. Wiseman GA, Leigh BR, Erwin WD, Sparks RB, Podoloff DA, Schilder RJ, et al. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. *Cancer Biother Radiopharm* (2003) **18**:165-78. doi:10.1089/108497803765036337

20. Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. *J Clin Oncol* (2002) **20**:3885-90. doi:10.1200/JCO.2002.10.143

21. Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. *Cancer* (2007) **22**(109):1804-10. doi:10.1002/cncr.22617

22. Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. *J Clin Oncol* (2005) **23**:7565-73. doi:10.1200/JCO.2004.00.9217

23. Hohloch K, Delaloye AB, Windemuth-Kieselbach C, Gómez-Codina J, Linkesch W, Jurczak W, et al. Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: registry analysis by the International radioimmunotherapy network. *J Nucl Med* (2011) **52**:1354-60. doi:10.2967/jnumed.111.089920

24. Emmanouilides C, Murray JL, Vo K, Witzig TE, Darif M, Schilder R, et al. Earlier treatment with yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy is associated with higher response rates and longer durations of response in patients with previously treated B-cell non-Hodgkin's lymphoma (NHL): results with second-line therapy (abstr 4949). *Blood* (2003) **102**:306b-7.

25. Davies AJ, Rohatiner AZ, Howell S, Britton KE, Owens SE, Micallef IN, et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. *J Clin Oncol* (2004) **22**:1469-79. doi:10.1200/JCO.2004.06.055

26. Illidge TM. Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date? *J Clin Oncol* (2010) **28**:2944-6. doi:10.1200/JCO.2009.26.8748

27. Czuczman MS, Emmanouilides C, Darif M, Witzig TE, Gordon LI, Revell S, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. *J Clin Oncol* (2007) **25**:4285-92. doi:10.1200/JCO.2006.09.2882

28. Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. *J Clin Oncol* (2005) **23**:712-9. doi:10.1200/JCO.2005.07.040

29. Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. *J Clin Oncol* (2003) **21**:1263-70. doi:10.1200/JCO.2003.08.043

30. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. *N Engl J Med* (2005) **352**:441-9. doi:10.1056/NEJMoa041511

31. Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I-131 tositumomab. *Blood* (2005) **105**:4576-82. doi:10.1182/blood-2004-12-4690

32. Dosik AD, Coleman M, Kostakoglu L, Furman RR, Fiore JM, Muss D, et al. Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. *Cancer* (2006) **106**:616-22. doi:10.1002/cncr.21606

33. Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. *J Clin Oncol* (1998) **16**:3270-8.

34. Gopal AK, Rajendran JG, Gooley TA, Pagel JM, Fisher DR, Petersdorf SH, et al. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults ≥60 years old with relapsed or refractory B-cell lymphoma. *J Clin Oncol* (2007) **25**:1396-402. doi:10.1200/JCO.2006.09.1215

35. Ferrucci PF, Vanazzi A, Grana CM, Cremonesi M, Bartolomei M, Chinol M, et al. High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas. *Br J Haematol* (2007) **139**:590-9. doi:10.1111/j.1365-2141.2007.06869.x

36. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, et al. Phase II trial of ¹³¹I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. *Lancet* (1995) **346**:336-40. doi:10.1016/S0140-6736(95)92225-3

37. Gopal AK, Rajendran JG, Petersdorf SH, Maloney DG, Eary JF, Wood BL, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. *Blood* (2002) **99**:3158-62. doi:10.1182/blood.V99.9.3158

38. Winter JN, Inwards DJ, Spies S, Wiseman G, Patton D, Erwin W, et al. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. *J Clin Oncol* (2009) **27**:1653-9. doi:10.1200/JCO.2008.19.2245

39. Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. *J Clin Oncol* (2005) **23**:461-7. doi:10.1200/JCO.2005.05.117
40. Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R, et al. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. *Exp Hematol* (2007) **35**:534–40. doi:10.1016/j.exphem.2007.01.043

41. Krishnan A, Nademanee A, Fung HC, Molina A, Yamauchi D, Rodriguez R, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. *J Clin Oncol* (2008) **26**:90–5. doi:10.1200/JCO.2007.11.9248

42. Krishnan A, Palmer JM, Tsai NC, Simpson JR, Nademanee A, Raubitschek A, et al. Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphoma. *Biol Blood Marrow Transplant* (2012) **18**:441–50. doi:10.1016/j.bbmtd.2011.07.016

43. Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R, et al. Cancer A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. *Cancer* (2012) **118**:4706–14. doi:10.1002/cncr.27418

44. Bethge WA, Lange T, Meisner C, von Harsdorf S, Bornhaeuser M, Federmann B, et al. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. *Blood* (2010) **116**:1795–802. doi:10.1182/blood-2010-02-270538

45. Gopal AK, Guthrie KA, Rajendran J, Pagel JM, Oliveira G, Maloney DG, et al. Y-IBritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. *Blood* (2011) **118**:1132–9. doi:10.1182/blood-2010-12-324392

46. Press OW, Unger JM, Rimsza LM, Friedberg JW, Leblanc M, Czuczman MS, et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus 131iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. *J Clin Oncol* (2013) **31**(3):314–20. doi:10.1200/JCO.2012.42.4101

47. Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. *Lancet* (2011) **377**:42–51. doi:10.1016/S0140-6736(10)62175-7

48. Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman RR, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. *J Clin Oncol* (2005) **23**:5696–704. doi:10.1200/JCO.2005.14.803

49. Hainsworth JD, Spigel DR, Markus TM, Shipley D, Thompson D, Rotman R, et al. Rituximab plus short-duration chemotherapy followed by yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. *Clin Lymphoma Myeloma* (2009) **9**:223–8. doi:10.3816/CLM.2009.n.044

50. Zinzani PL, Rossi G, Franceschetti S, Botto B, Di Rocco A, Cabras MG, et al. Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. *Clin Cancer Res* (2010) **16**:3998–4004. doi:10.1158/1078-0432.CCR-10-0162

51. Smith MR, Li H, Gordon L, Gascoyne RD, Paietta E, Forero-Torres A, et al. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. *J Clin Oncol* (2012) **30**:3119–26. doi:10.1200/JCO.2012.42.2444

52. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. *J Clin Oncol* (2009) **27**:5213–8. doi:10.1200/JCO

53. Illidge TM, Pettengell R, Bayne M, Le Gouill S, Bates A, Radford J, et al. Fractionated ⁹⁰Y ibritumomab tiuxetan (Zevalin™) radioimmunotherapy as an initial therapy of follicular lymphoma – first results from a phase II study in patients requiring treatment according to GELF/BNLI criteria. *Blood* (2011) **118**:102.

54. Scholz CW, Pinto A, Linkesch W, Lindén O, Viardot A, Keller U, et al. 90Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. *J Clin Oncol* (2013) **31**(3):308–13. doi:10.1200/JCO.2011.41.1553

55. Ghiemmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. *Blood* (2004) **103**:4416–23. doi:10.1182/blood-2003-10-3411

56. Griffith MH, Yorke ED, Wesels BW, DeNardo GL, Neacy WP. Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy. *J Nucl Med* (1988) **29**:1795–809.

57. DeNardo GL, Slom J, Buchsbaum D, Meredith RF, O'Donoghue JA, Sgouros G, et al. Ratiosales, evidence, and design considerations for fractionated radioimmunotherapy. *Cancer* (2002) **94**:1332–48. doi:10.1002/cncr.10304

58. DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, Lamborn KR, Levy NB, et al. Maximum tolerated dose, toxicity, and efficacy of ¹³¹I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. *J Clin Oncol* (1998) **16**:3246–56.

59. Illidge TM, Bayne M, Brown NS, Chilton S, Cragg MS, Glennie MJ, et al. Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab

dosing and tumor burden on subsequent radioimmunotherapy. *Blood* (2009) **113**:1412–21. doi:10.1182/blood-2008-08-175653

60. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. *J Clin Oncol* (2006) **24**:823–34. doi:10.1200/JCO.2005.03.8471

61. Chatal JF, Campion L, Kraeber-Bodéré F, Bardet S, Vuillez JP, Charbonnel B, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. *J Clin Oncol* (2006) **24**:1705–11. doi:10.1200/JCO.2005.04.4917

62. Manetti C, Rouvier E, Gautherot E, Loucif E, Barbet J, Le Doussal JM. Targeting BCL1 lymphoma with anti-idiotype antibodies: biodistribution kinetics of directly labeled antibodies and bispecific antibodies-targeted bivalent haptens. *Int J Cancer* (1997) **71**:1000–9. doi:10.1002/(SICI)1097-0215(19970611)71:6<1000::AID-IJC16>3.3.CO;2-Q

63. Press OW, Corcoran M, Subbiah K, Hamlin DK, Wilbur DS, Johnson T, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. *Blood* (2001) **98**:2535–43. doi:10.1182/blood.V98.8.2535

64. Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Gaffigan S, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. *Cancer Biother Radiopharm* (2000) **15**:15–29. doi:10.1089/cbr.2000.15.15

65. Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins J, et al. Phase I trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. *Blood* (2004) **104**:227–36. doi:10.1182/blood-2003-09-3284

66. Sharkey RM, Karacay H, Litwin S, Rossi EA, McBride WJ, Chang CH, et al. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.
*Cancer Res* (2008) **68**:5282-90.
doi:10.1158/0008-5472.CAN-08-0037

67. Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, et al. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. *Blood* (2010) **116**:4231-9. doi:10.1182/blood-2010-05-282327

68. Juweid M. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. *J Nucl Med* (2002) **43**:1507-29.

69. O'Donnell RT, Shen S, Denardo SJ, Wun T, Kukis DL, Goldstein DS, et al. A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. *Anticancer Res* (2000) **20**:3647-55.

70. Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, et al. Radioimmunotherapy of non-Hodgkin's lymphoma with ⁹⁰Y-DOTA humanized anti-CD22 IgG (90Y-epratuzumab): do tumor targeting and dosimetry predict therapeutic response? *J Nucl Med* (2003) **44**:2000-18.

71. Lindén O, Hindorf C, Cavallin-Ståhl E, Wegener WA, Goldenberg DM, Horne H, et al. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. *Clin Cancer Res* (2005) **11**:5215-22. doi:10.1158/1078-0432.CCR-05-0172

72. Morschhauser F, Kraeber-Bodéré F, Wegener WA, Harousseau JL, Petillon MO, Huglo D, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. *J Clin Oncol* (2010) **28**:3709-16. doi:10.1200/JCO.2009.27.7863

73. Kraeber-Bodéré F, Pallardy A, Le Gouill S, Maisonneuve H, Lamy T, Krimo Bouabdallah K, et al. Consolidation anti-CD22 fractionated radioimmunotherapy with ⁹⁰Y-epratuzumab tetraxetan following R-CHOP in elderly DLBCL patients: a lysa phase II prospective trial. *Blood* (2012) **120**:906.

74. Mattes MJ, Sharkey RM, Karacay H, Czuczman MS, Goldenberg DM. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (velutuzumab). *Clin Cancer Res* (2008) **14**:6154-60. doi:10.1158/1078-0432.CCR-08-0404

75. Sharkey RM, Karacay H, Johnson CR, Litwin S, Rossi EA, McBride WJ, et al. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. *J Nucl Med* (2009) **50**:444-53. doi:10.2967/jnumed.108.058602

76. Perk LR, Visser OJ, Stigter-van WalsumM, Vosjan MJ, Visser GW, Zijlstra JM, et al. Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography. *Eur J Nucl Med Mol Imaging* (2006) **33**(11):1337-45. doi:10.1007/s00259-006-0160-0

77. Bardiès M, Buvat I. Dosimetry in nuclear medicine therapy: what are the specifics in image quantification for dosimetry? *Q J Nucl Med Mol Imaging* (2011) **55**:5-20.

78. Wahl RL, Zasadny KR, MacFarlane D, Francis IR, Ross CW, Estes J, et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan phase I experience. *J Nucl Med* (1998) **39**(8 Suppl):21S-7.

79. Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, et al. Phase I/II

90Y-Zevalin (yttrium-90 ibrityumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. *Eur J Nucl Med* (2000) **27**:766-77. doi:10.1007/s002590000276

80. Delaloye AB, Antonescu C, Louton T, Kuhlmann J, Hagenbeek A. Dosimetry of 90Y-ibrityumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial. *J Nucl Med* (2009) **50**:1837-43. doi:10.2967/jnumed.109.067587

81. Ferrer L, Malek E, Bodet-Milin C, Legouill S, Prangère T, Robu D, et al. Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma. *Q J Nucl Med Mol Imaging* (2012) **56**:529-37.

82. He B, Wahl RL, Sgouros G, Du Y, Jacene H, Kasecamp WR. Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning – patient studies. *Med Phys* (2009) **36**:1595-601. doi:10.1118/1.3100265

83. Sjögreen-Gleisner K, Dewaraja YK, Chiesa C, Tennvall J, Lindén O, Strand SE, et al. Dosimetry in patients with B-cell lymphoma treated with [(90)Y]ibrityumomab tiuxetan or [(131)I]tositumomab. *Q J Nucl Med Mol Imaging* (2011) **55**:126-54.

84. Dewaraja YK, Schipper MJ, Roberson PL, Wilderman SJ, Amro H, Regan DD. 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling. *J Nucl Med* (2010) **51**:1155-62. doi:10.2967/jnumed.110.075176

85. DeNardo GL, DeNardo SJ, Lamborn KR, Goldstein DS, Levy NB, Lewis JP, et al. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. *Cancer Biother

*Radiopharm* (1998) **13**:239-54. doi:10.1089/cbr.1998.13.239

86. Sharkey RM, Press OW, Goldenberg DM. A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. *Blood* (2009) **113**:3891-5. doi:10.1182/blood-2008-11-188896

87. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. *J Clin Oncol* (2002) **20**:2453-63. doi:10.1200/JCO.2002.11.017

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 21 March 2013; paper pending published: 29 April 2013; accepted: 21 June 2013; published online: 11 July 2013. Citation: Bodet-Milin C, Ferrer L, Pallardy A, Eugène T, Rauscher A, Faivre-Chauvet A, Barbet J and Kraeber-Bodéré F (2013) Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. *Front. Oncol.* **3**:177. doi: 10.3389/fonc.2013.00177

This article was submitted to Frontiers in Radiation Oncology, a specialty of Frontiers in Oncology.

Copyright © 2013 Bodet-Milin, Ferrer, Pallardy, Eugène, Rauscher, Faivre-Chauvet, Barbet and Kraeber-Bodéré. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.